Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation.
Islet transplantation
chemokine receptors
chemokines
immune modulation
immunosuppressive regimens
induction
Journal
Cell transplantation
ISSN: 1555-3892
Titre abrégé: Cell Transplant
Pays: United States
ID NLM: 9208854
Informations de publication
Date de publication:
Historique:
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
18
11
2021
Statut:
ppublish
Résumé
A recent randomized, multicenter trial did not show benefit of a CXCR1/2 receptor inhibitor (Reparixin) when analysis included marginal islet mass (>3,000 IEQ/kg) for allotransplantation and when immunosuppression regimens were not standardized among participating centers. We present a post-hoc analysis of trial patients from our center at the University of Chicago who received an islet mass of over 5,000 IEQ/kg and a standardized immunosuppression regimen of anti-thymocyte globulin (ATG) for induction. Twelve islet allotransplantation (ITx) recipients were randomized (2:1) to receive Reparixin (
Identifiants
pubmed: 33908301
doi: 10.1177/09636897211001774
pmc: PMC8085379
doi:
Substances chimiques
Immunosuppressive Agents
0
Banques de données
ClinicalTrials.gov
['NCT01817959']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9636897211001774Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK020595
Pays : United States
Références
Lancet Diabetes Endocrinol. 2013 Dec;1(4):306-16
pubmed: 24622416
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Int J Endocrinol. 2014;2014:451035
pubmed: 24883060
Ups J Med Sci. 2000;105(2):125-33
pubmed: 11095109
Breast Cancer Res. 2020 Jan 10;22(1):4
pubmed: 31924241
Cell Transplant. 2019 Feb;28(2):185-194
pubmed: 30520321
Am J Transplant. 2012 Jun;12(6):1576-83
pubmed: 22494609
Am J Transplant. 2018 Apr;18(4):990-997
pubmed: 29218834
Diabetes. 2013 Aug;62(8):2890-7
pubmed: 23630300
Transplantation. 2014 Nov 15;98(9):1007-12
pubmed: 24911037
Radiographics. 2010 Mar;30(2):353-66
pubmed: 20228322
Islets. 2016 Sep 2;8(5):115-24
pubmed: 27328412
Am J Transplant. 2010 Aug;10(8):1870-80
pubmed: 20659093
Am J Transplant. 2020 Mar;20(3):844-851
pubmed: 31597009
Diabetes. 2016 Nov;65(11):3418-3428
pubmed: 27465220
JAMA. 2005 Feb 16;293(7):830-5
pubmed: 15713772
N Engl J Med. 2000 Jul 27;343(4):230-8
pubmed: 10911004
Diabetes Care. 2020 Apr;43(4):710-718
pubmed: 32019854
Diabetes Care. 2016 Sep;39(9):1602-13
pubmed: 27407117
Transplantation. 2020 Jan;104(1):190-196
pubmed: 31365472
CellR4 Repair Replace Regen Reprogram. 2019;7:
pubmed: 32149162
Transplantation. 2015 Aug;99(8):1568-73
pubmed: 25769078
J Clin Endocrinol Metab. 2019 Feb 1;104(2):451-460
pubmed: 30203041
Diabetes Care. 2016 Jul;39(7):1230-40
pubmed: 27208344
Am J Transplant. 2016 Sep;16(9):2704-13
pubmed: 27017888
Diabetes Care. 2005 Feb;28(2):343-7
pubmed: 15677790
Transplantation. 2015 May;99(5):979-84
pubmed: 25393157
Transpl Int. 2018 Apr;31(4):343-352
pubmed: 29453879
Transplant Proc. 2017 Dec;49(10):2340-2346
pubmed: 29198674
Am J Transplant. 2021 Apr;21(4):1365-1375
pubmed: 33251712
Curr Diab Rep. 2011 Oct;11(5):345-54
pubmed: 21830042
J Clin Invest. 2012 Oct;122(10):3647-51
pubmed: 22996693
Diabetes Care. 2008 Feb;31(2):301-5
pubmed: 17977937
Rev Diabet Stud. 2012 Winter;9(4):385-406
pubmed: 23804275
CellR4 Repair Replace Regen Reprogram. 2019;7:
pubmed: 33834084